Advertisements
Feeds:
Posts
Comments

Archive for the ‘Scientist: Career considerations’ Category


Newly Elect President of Technion, Professor Uri Sivan: Key Contributions to Scientific Innovations

 

Reporter: Aviva Lev-Ari, PhD, RN

 

February 7, 2019
By: Office of the Technion Spokesperson

The Technion Council, headed by Mr. Gideon Frank, has elected Professor Uri Sivan of the Faculty of Physics as the next president of Technion. The Council’s decision was based on the recommendation of the Search Committee for the Technion President and received sweeping support from the Academic Assembly. The appointment is subject to the final approval of the International Board of Governors, which is set to convene in June.

Professor Uri Sivan

Prof. Sivan will commence his term as President of Technion on October 1 2019, and will replace the outgoing President Prof. Peretz Lavie, who will complete his term after a decade in office.

Prof. Sivan, 64, a resident of Haifa, is married and the father of three. He served as a pilot in the Israeli Air Force. He has a BSc in Physics and Mathematics, an MSc and PhD in Physics, all with honors from Tel Aviv University.

In 1991, after three years at IBM’s T. J. Watson Research Center in New York, Prof. Sivan joined the Faculty of Physics at Technion.

SOURCE

https://ats.org/news/professor-uri-sivan-elected-new-president-of-the-technion/

 

Key Contributions to Scientific Innovations

  • His research has covered a wide range of fields including quantum mesoscopic physics and the harnessing of molecular and cellular biology for the self-assembly of miniature electronic devices. Prof. Sivan, along with colleagues Profs. Erez Braun and Yoav Eichen, demonstrated for the first time how to harness molecular recognition by DNA molecules for wiring an electric circuit. This study gained considerable resonance and helped pave the way for a new field in nanotechnology using the self-assembly properties of biological molecules to construct miniature engineering systems.
  • His research has focused on the way water orders next to molecules and the effect of this ordering on inter-molecular interactions in biologically relevant solutions. Within this framework, Prof. Sivan’s group designs and builds unique, ultra-high-resolution atomic force microscopes.
  • His research has led to patents and industrial applications. Recently, an Israeli start-up company was established in the field of single cell analysis for cancer diagnostics, based on the technology developed in Prof. Sivan’s lab.
  •  Prof. Sivan is the founding director of the Russell Berrie Nanotechnology Institute (RBNI), which he headed between 2005 and 2010.  RBNI has led the scientific revolution in nanotechnology at Technion and has placed the university at the forefront of global research in the field. RBNI made headlines when Prof. Sivan and Dr. Ohad Zohar engraved the entire Hebrew Bible onto a tiny silicon chip. The Nano Bible was written as part of an educational program developed by the Institute to increase young people’s interest in science and especially in nanotechnology. In 2009, President Shimon Peres presented the Nano Bible to Pope Benedict XVI during his official visit to Israel. Today, there are three copies of the chip worldwide: at the Vatican Library, the Smithsonian Museum in Washington D.C., and the Israel Museum in Jerusalem. The establishment of RBNI spearheaded the development of Israel’s national nanotechnology program, and together with centers established in other Israeli universities, has positioned the country as a world leader in nanotechnology.

APPOINTMENTS

Recently, Prof. Sivan was appointed to head the National Advisory Committee in Quantum Science and Technology of the Council for Higher Education’s Planning and Budgeting Committee (PBC). The committee outlined the national quantum academic program, which was adopted and launched last year.

Prof. Sivan has served as a member of the Israeli National Committee for Research and Development (MOLMOP) and the Scientific Advisory Committee of the Batsheva de Rothschild Foundation. He currently serves on the Advisory Committee of the Maof Fellowships Committee for advancing Arab faculty and is a member of the Israeli Wolfson Foundation Advisory Board.

AWARDS

Prof. Sivan is a renowned lecturer in Israel and abroad. He was awarded with numerous prizes including

  • the Mifal Hapais Landau Prize for the Sciences and Research,
  • the Rothschild Foundation Bruno Prize,
  • the Israel Academy of Sciences Bergmann Prize,
  • the Technion’s Hershel Rich Innovation Award, and
  • the Taub Award for Excellence in Research.

 

SOURCE

https://ats.org/news/professor-uri-sivan-elected-new-president-of-the-technion/

Advertisements

Read Full Post »


eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model

Author: Aviva Lev- Ari, PhD, RN

 

Six demonstrations that justify the claims made in our 2019 VISION:

https://pharmaceuticalintelligence.com/vision/

  • Point #1: Top Author, Chief Scientific Officer, MD, FCAP – share in the Journal’s archive computed
  • Point #2: Top authors by e-Readers per article – A Team at work
  • Point #3: Team members Led by Key Opinion Leader [https://lnkd.in/eEyn69r] generated Intellectual Property (IP) of Three Asset Classes
  • Point #4: Functions and Forms by Asset Class
  • Point #5: SYNERGY among the Three Asset Classes stimulates Value Creation
  • Point #6: Plan for Team membership augmentation and Training under existing Leadership and New Ownership

 

POINT #1: Top Author, Chief Scientific Officer, a retired Chief of Pathology, LHB, MD, FCAP – share in the Journal’s archive computed

Journal archive has 5,486 articles published

LHB has published 1,390 articles = 25.33% – he joined our team with a publication list of +200 articles in referred academic journals. LHB is co-curator of many articles with many of the team members

  • The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy– The Best Writers Among the WRITERS

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

 

POINT #2: Top authors by e-Readers per article – A Team at work

Click on this link to review the contributions of Team members who’s articles achieved >1,000 Views.

  • Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com

https://pharmaceuticalintelligence.com/2019/01/30/article-title-author-curators-name-and-article-views-1000-4-2012-1-2018-pharmaceuticalintelligence-com/

 

POINT #3: Team members led by Key Opinion Leader (KOL) [https://lnkd.in/eEyn69r] generated Intellectual Property (IP) of Three Asset Classes

 

List of LPBI IP Assets by Asset Class representing a Team Effort

 

  • IP Asset Class I: Launched Open Access Online Scientific Journal @com, 4/2012

https://lnkd.in/erfbayJ

  •  IP Asset Class II: Launched BioMed eSeries, 16-Volumes in Life Sciences and Medicine, 10/2012

BioMed e-Series: 16 Volumes – electronic Table of Contents (eTOCs) of each Volume

https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/


Launched 6 Volumes Cardiovascular Diseases e-Series, Bundled on Amazon for $515

https://lnkd.in/e6WkMgF

Launched 10 Volumes in Medicine: Genomics 1,2  Cancer 1,2 Immunology 1,2,3  Precision Medicine 1,2,3,4

https://lnkd.in/ekWGNqA

 

  • IP Asset Class III: Launched Real Time Press Coverage of Biotech Conferences, 3/2013

https://pharmaceuticalintelligence.com/press-coverage/

Part One: The Process of Real Time Coverage using Social Media

Part Two: List of BioTech Conferences 2013 to Present

Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

 

POINT #4: FUNCTIONS and FORMS by ASSET CLASS

 

LPBI Group’s IP:VENTURE’s Future Potential
IP Asset Class I
https://lnkd.in/erfbayJ
IP Asset Class II
https://lnkd.in/ekWGNqA
IP Asset Class III
https://pharmaceuticalintelligence.com/press-coverage/
Open Access Journal– M1.5 e-Readers,- 5.5K articles- 670 categories,- 7.3K comments- 10K Tags
BioMed E-Series– 16 Volumes- 5 Specialties in Medicine- 6 Volumes Cardiovascular Diseases e-Series, Bundled on Amazon for $515https://lnkd.in/e6WkMgF
Real Time Coverage BioTech/Medicine Conferences– eProceedings- Real Time Tweets on- Two Twitter Handles- Conference Hash Tags@pharma_BI@AVIVA1950- Part Two: List of BioTech Conferences 2013 to Present
Editor-in-Chief’sLeadership:- Senior Editors- Our Team
Our Team’s Product
https://pharmaceuticalintelligence.com/contributors-biographies/
Senior Editors’ Product with Our Team
https://pharmaceuticalintelligence.com/contributors-biographies/senior-editors/https://pharmaceuticalintelligence.com/contributors-biographies/
Editor-in-Chief’s Initiative
https://lnkd.in/eEyn69r
Architecture   Methodologies for ourPlatforms
·       Multi-Authoring Platform – wordpress.com·       Authoring Privilege levels·       Categories of research forming the Journal’s Ontology, a Dynamic Relational and Hierarchical database Multi-Authoring architecture·       Generation of new categories by authors developing the categories they are Owners of·       Article update policy
·       eTOCs design by Editors·       e-Book Style uniformity across all eSeries·       Structure of eBook Parts·       Structure of Chapters·       Structure of Articles·       Commission of Articles Specifically for given e-Books by Editor-in-Chief·       Overarching guidance for e-Books within each eSeries and across eSeries
·       Part One: The Process of Real Time Coverage using Social Media·       Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA·       Template Development Process·       Channels of Social Media Development
Business ModelDevelopment: Content Creation by Curation of Scientific Findings
·       Author/Curator initiated article·       Article Commissions by Editor-in-Chief·       Co-Curations·       Research Category Ownership·       e-Books Editors role defined (Job description)
·       e-Books in Kindle Store·       30,000 Oncologists in the US·       40,000 Cardiologists in the US·       All Primary Care Physicians·       All Medical Schools for Curriculum development·       Global market for Medical EducationALL BioMed 16 Volumes [$515+$190+$175+$190+$274 = $1,344]@Amazon BUNDLED 6 Volumes Cardiovascular Diseases for $515https://lnkd.in/e6WkMgF@Amazon UNBUNDLED 10 Volumeshttps://lnkd.in/ekWGNqA·       Genomics 1,2 ($190)·       Cancer 1,2 ($175)·       Metabolomics, Immunology, Infectious Diseases 1,2,3 (#190)·       Precision Medicine 1,2,3,4 ($274)
·       The market is defined as “All Biotech Conferences Organizers around the Globe” in need to own eProceedings for their Conferences for electronic dissemination to conference attendees.·       Digital Archive of Conferences eProceedingsPart Three: Conference eProceedings DELIVERABLES & Social Media Analytics
 
IP Asset Class III
https://pharmaceuticalintelligence.com/press-coverage/
Real Time Coverage BioTech/Medicine Conferences
– eProceedings
– Real Time Tweets on
– Two Twitter Handles
– Conference Hash Tags
@pharma_BI
@AVIVA1950
Part Two: List of BioTech Conferences 2013 to Present
Editor-in-Chief’s Initiative
https://lnkd.in/eEyn69r
·       Part One: The Process of Real Time Coverage using Social Media
·       Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA
·       Template Development Process
·       Channels of Social Media Development
·       The market is defined as “All Biotech Conferences Organizers around the Globe” in need to own eProceedings for their Conferences for electronic dissemination to conference attendees.
·       Digital Archive of Conferences eProceedings
Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

POINT #4 (IN DETAIL): Functions and Forms by Asset Class

 

IP Asset Class I: The Journal

 

The Methodology of Curation for Scientific Research Findings

https://pharmaceuticalintelligence.com/2014/07/30/the-methodology-of-curation-for-scientific-research-findings/

 

>> Evolution of Platform Architecture Methodologies: 

  • Multi-Authoring Platform – wordpress.com
  • Authoring Privilege levels
  • Categories of research forming the Journal’s Ontology, a Dynamic Relational and Hierarchical database Multi-Authoring architecture
  • Generation of new categories by authors developing the categories they are Owners of
  • Article update policy

 

>> Intellectual Property Development (Content Creation by Curation) Business Model 

  • Author/Curator initiated article
  • Article Commissions by Editor-in-Chief
  • Co-Curations
  • Research Category Ownership
  • e-Books Editors role defined (Job description)

 

IP Asset Class II: BioMed e-Series

 

> Evolution of Platform Architecture Methodologies

Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation

https://pharmaceuticalintelligence.com/2013/07/29/cardiovascular-original-research-cases-in-methodology-design-for-content-curation-and-co-curation/

  • eTOCs design by Editors
  • e-Book Style uniformity across all eSeries
  • Structure of eBook Parts
  • Structure of Chapters
  • Structure of Articles
  • Commission of Articles Specifically for given e-Books by Editor-in-Chief
  • Overarching guidance for e-Books within each eSeries and across eSeries

 

> Intellectual Property Development (Content Creation by Curation) Business Model 

 

  • e-Books in Kindle Store
  • 30,000 Oncologists in the US
  • 40,000 Cardiologists in the US
  • US & Global markets for Cardiology, Genomics, Cancer, Immunology, Infectious Diseases, Precision Medicine
  • All Primary Care Physicians
  • All Medical Schools for Curriculum development
  • Global market for Medical Education

 

ALL BioMed 16 Volumes [$515+$190+$175+$190+$274 = $1,344]

@Amazon BUNDLED 6 Volumes Cardiovascular Diseases for $515 https://lnkd.in/e6WkMgF

@Amazon UNBUNDLED 10 Volumes in #Medicine https://lnkd.in/ekWGNqA

  • Genomics 1,2 ($190)
  • Cancer 1,2 ($175)
  • Metabolomics, Immunology, Infectious Diseases 1,2,3 (#190)
  • Precision Medicine 1,2,3,4 ($274)

 

Series A – Cardiovascular Diseases – 6 volumes $515

 

Series B – Genomics 1,2  – 2 volumes $190

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On comsince 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

Volume 2 is Work-in-Progress To Be Published in 6/2019 at $115

 

Series C – Cancer & Oncology $175 

  • VOLUME 1 Cancer Biology Genomics

http://www.amazon.com/dp/B013RVYR2K

  • VOLUME 2 Therapies Genomics Interventional Immunotherapy Nanotechnology in Drug Delivery

http://www.amazon.com/dp/B071VQ6YYK

 

Series D – Metabolomics, Immunology, Infectious Diseases $190

  • VOLUME 1 Metabolomics

http://www.amazon.com/dp/B012BB0ZF0

  • VOLUME 2 Infectious Diseases & VOLUME 3 Immunology

https://www.amazon.com/dp/B075CXHY1B

 

Series E Precision Medicine – Four Volumes, Volumes 1,2,3,4 at $274

  • Patients Voices

https://www.amazon.com/dp/B076HGB6MZ

  • Physiology and Therapeutics

https://www.amazon.com/dp/B078313281

  • Medical Discoveries: Genomics Therapeutics

http://www.amazon.com/dp/B019VH97LU

  • 3D #BioPrinting in Medicine for Precision Medicine

https://www.amazon.com/dp/B078QVDV2W

 

IP Asset Class III: Real Time Coverage of BioTech Conferences

 

>> Evolution of Platform Architecture Methodologies

https://pharmaceuticalintelligence.com/2014/04/07/methodology-for-conference-coverage-using-social-media-2014-massbio-annual-meeting-43-44-2014-royal-sonesta-hotel-cambridge-ma/

  • Template Development Process
  • Channels of Social Media Development

 

>> Intellectual Property Development (Content Creation by Curation) Business Model 

  • The market is defined as “All Biotech Conferences Organizers around the Globe” in need to own eProceedings for their Conferences for electronic dissemination to conference attendees.
  • Digital Archive of Conferences eProceedings

 

POINT #5: SYNERGY among the Three Asset Classes stimulates Value Creation

 

  • Concepts from +60 Conferences I covered yielded ~300 new articles, five new per conference, at least
  • Electronic Table of Contents [eTOCs] for each e-Book of the [1,2,3..,16] is derived from the Research categories of the Journal
  • Journal Ontology has 700 Research Categories – knowledge architecture designed by experts
  • Every article in the Journal is connected with Social Media Icons on wordpress.com as an engine for
  1. Pingbacks
  2. New eReaders
  3. Scientists applying to author for the Journal
  4. +7,300 Scientific comments on 5,486 articles published – AGORA  

Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case Studies

https://pharmaceuticalintelligence.com/2018/04/10/electronic-scientific-agora-comment-exchanges-by-global-scientists-on-articles-published-in-the-open-access-journal-pharmaceuticalintelligence-com-four-case-studies/

 

POINT #6: Plan for Team membership augmentation and Training under existing Leadership and New Ownership

Work-in-Progress

 

 

Other related articles published in this Open Access Online Scientific Journal include the following: 

 

Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

https://pharmaceuticalintelligence.com/2017/05/06/case-studies-of-innovations-in-electronic-scientific-publishing-esp-marketing-econtent-curation-methodology-categories-of-research-functions-interdisciplinary-conceptual-innovations-by-cross-sec/

 

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

 

The Methodology of Curation for Scientific Research Findings

https://pharmaceuticalintelligence.com/2014/07/30/the-methodology-of-curation-for-scientific-research-findings/

 

@PharmaceuticalIntelligence.com – A Case Study on the LEADER in Curation of Scientific Findings

https://pharmaceuticalintelligence.com/2017/06/29/pharmaceuticalintelligence-com-a-case-study-on-the-leader-in-curation-of-scientific-findings/

 

Curation of Scientific Content @Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

https://pharmaceuticalintelligence.com/2016/08/15/curation-of-scientific-content-leaders-in-pharmaceutical-business-intelligence-lpbi-group-boston/

 

Scientific Curation Fostering Expert Networks and Open Innovation: Lessons from Clive Thompson

https://pharmaceuticalintelligence.com/2014/07/17/scientific-curation-fostering-expert-networks-and-open-innovation-lessons-from-clive-thompson-and-others/

 

Cardiovascular Diseases and Pharmacological Therapy: Curations by Aviva Lev-Ari, PhD, RN, 2006 – 4/2018

https://pharmaceuticalintelligence.com/2014/04/17/cardiovascular-diseases-and-pharmacological-therapy-curations-by-aviva-lev-ari-phd-rn/

 

Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA

https://pharmaceuticalintelligence.com/2014/04/07/methodology-for-conference-coverage-using-social-media-2014-massbio-annual-meeting-43-44-2014-royal-sonesta-hotel-cambridge-ma/

 

Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation

https://pharmaceuticalintelligence.com/2013/07/29/cardiovascular-original-research-cases-in-methodology-design-for-content-curation-and-co-curation/

 

 

 

 

Read Full Post »


Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com

 

Reporter: Aviva Lev-Ari, PhD, RN

 

Expert, Author, Writer’s Initials

Name & Bio

Roles

@LPBI Group

LHB Larry Bernstein, MD, FACP,

 

Member of the Board

Expert, Author, Writer – All Specialties of Medicine & Pathology

Content Consultant to Series B,C,D,E

Editor, Series D, Vol. 1, Series E, Vols 2,3,

Co-Editor – BioMed E-Series 13 of the 16 Vols

JDP Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC,

 

Expert, Author, Writer, All Specialties of Medicine, Cardiology and Cardiac Imaging

Content Consultant for SERIES A, Cardiovascular Diseases Co-Editor: Vols 2,3,4,5,6

ALA Aviva Lev-Ari, PhD, RN,

-Ex – SRI, Int’l

-Ex – MITRE

-Ex – McGraw-Hill

Director and Founder

Editor-in-Chief, @pharmaceuticalintelligence.com

Methodologies Developer:

  • Journal Platform Architect,
  • CURATION of Scientific Findings Modules,
  • REALTIME eProceedings Digital 1-Click Publishing

Expert, Author, Writer:

  • Analytics
  • Molecular Cardiology
  • Vascular Biology
TB Tilda Barliya, PhD,

@BIU

Expert, Author, Writer: Nanotechnology for Drug Delivery

Co-Editor, Series C, Vols. 1,2

DN Dror Nir, PhD,

 

Expert, Author, Writer: Cancer & Medical Imaging Algorithms
ZR       
Ziv Raviv, PhD,
@Technion
Expert, Author, Writer: Biological Sciences, Cancer
ZS Zohi Sternberg, PhD, Expert, GUEST Author, Writer

 

Expert, GUEST Author, Writer

Neurological Sciences

SJW Stephen J. Williams, PhD Pharmacology, BSc Toxicology

Ex-Fox Chase

EAW – Cancer Biology

Co-Editor, Series A, Vol.1

Co-Editor, Series B, Genomics: Vols. 1,2

Co-Editor, Series C, Cancer, Vols. 1,2

DS Demet Sag, PhD, CRA, GCP,

 

Expert, Author, Writer: Genome Biology, Immunology, Biological Sciences: Cancer
SS Sudipta Saha, PhD,

 

Expert, Author, Writer: Reproductive Biology, Endocrinology, Bio-Instrumentation

Co-Editor, Series D, Volume 2, Infectious Diseases

AV Aviral Vatsa, PhD, MBBS

 

Expert, Author, Writer: Medical Sciences, Bone Disease, Human Sensation and Cellular Transduction: Physiology and Therapeutics

 

RS Ritu Saxena, PhD,

 

Expert, Author, Writer: Biological Sciences, Bone Disease, Cancer (Lung, Liver)
GST Gail S. Thornton, PhD(c),

Ex-MERCK

Contributing Editor, Author and Medical Writer

Co-Editor, Series E, Vol.1 Voices of Patients

RN Raphael Nir, PhD, MSM, MSc

Ex-ScheringPlough

– Expert, Author, Writer – Member of the Cancer Research Team: Brain Cancer, Liver Cancer, Cytokines

– CSO, SBH Sciences, Inc.

MB Michael R. Briggs, Ph.D.

Ex-Pfizer

– Expert, Author, Writer – Member of the Cancer Research Team: NASH

– CSO, Woodland Biosciences

AK Alan F. Kaul, R.Ph., Pharm.D, M.Sc., M.B.A., FCCP, Expert, Author, Writer

Ex-Director BWH Pharmacy

Expert, Author, Writer: Pharmacology – all aspects of Drug development and dispensation, Policy analyst
AS Anamika Sarkar, PhD,

 

Expert, Author, Writer: Computation Biology & Bioinformatics
MWF Marcus Feldman, PhD,

Stanford University, Biological Sciences, Center for Genomics

751
Research items
51,402
Reads
39,126
Citations
Member of the Board,

Scientific Counsel: Life Sciences,

Content Consultant Series B, Genomics, Vols. 1,2

Co-Editor, Vol. 2, NGS

 

Article Title and Views >1,000,

4/2012 – -1/2018

 

 

 

 

Home page / Archives

Authors

Curators

Reporters

by Name

 

Views

by 

eReaders

 

 

 

 

 

600,145

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? LHB 16,720
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)

JDP

ALA

13,225
Paclitaxel vs Abraxane (albumin-bound paclitaxel) TB 11,872
Recent comprehensive review on the role of ultrasound in breast cancer management DN 11,715
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care ALA 7,045
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications ALA 6,435
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) TB 6,309
Our TEAM ALA 6,213
Akt inhibition for cancer treatment, where do we stand today? ZR 4,744
Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects LHB 4,508
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses ZS 4,188
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation SJW 4,128
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad DS 3,678
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets LHB 3,652
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules SJW 3,625
Cardiovascular Diseases, Volume One: Perspectives on Nitric Oxide in Disease Mechanisms Multiple

Authors

3,575
Interaction of enzymes and hormones SS 3,546
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo SJW 3,403
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging DN 3,399
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology TB 3,371
Founder ALA 3,363
BioMed e-Series ALA 3,246
Signaling and Signaling Pathways LHB 3,178
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment SS 3,044
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community

JDP

LHB

ALA

3,034
The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) Dr. Karra 3,016
VISION ALA 2,988
Targeting the Wnt Pathway [7.11] LHB 2,961
Bone regeneration and nanotechnology AV 2,922
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) ALA 2,892
The History and Creators of Total Parenteral Nutrition LHB 2,846
Funding, Deals & Partnerships ALA 2,708
Paclitaxel: Pharmacokinetic (PK), Pharmacodynamic (PD) and Pharmacogenpmics (PG) TB 2,700
LIK 066, Novartis, for the treatment of type 2 diabetes LHB 2,693
FDA Adds Cardiac Drugs to Watch List – TOPROL-XL® ALA 2,606
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation LHB 2,579
Nitric Oxide and Platelet Aggregation Dr. Karra 2,550
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical) LHB 2,549
Isoenzymes in cell metabolic pathways LHB 2,535
“The Molecular pathology of Breast Cancer Progression” TB 2,491
In focus: Circulating Tumor Cells RS 2,465
Nitric Oxide Function in Coagulation – Part II LHB 2,444
Monoclonal Antibody Therapy and Market DS 2,443
Update on FDA Policy Regarding 3D Bioprinted Material SJW 2,410
Journal PharmaceuticalIntelligence.com ALA 2,340
A Primer on DNA and DNA Replication LHB 2,323
Pyrroloquinoline quinone (PQQ) – an unproved supplement LHB 2,294
Integrins, Cadherins, Signaling and the Cytoskeleton LHB 2,265
Evolution of Myoglobin and Hemoglobin LHB 2,251
DNA Structure and Oligonucleotides LHB 2,187
Lipid Metabolism LHB 2,176
Non-small Cell Lung Cancer drugs – where does the Future lie? RS 2,143
Biosimilars: CMC Issues and Regulatory Requirements ALA 2,101
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research SJW 2,092
About ALA 2,076
Sex Hormones LHB 2,066
CD47: Target Therapy for Cancer TB 2,041
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes ALA 2,017
Swiss Paraplegic Centre, Nottwil, Switzerland – A World-Class Clinic for Spinal Cord Injuries GST 1,989
Introduction to Tissue Engineering; Nanotechnology applications TB 1,964
Problems of vegetarianism SS 1,940
The History of Infectious Diseases and Epidemiology in the late 19th and 20th Century LHB 1,817
The top 15 best-selling cancer drugs in 2022 & Projected Sales in 2020 of World’s Top Ten Oncology Drugs ALA 1,816
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node TB 1,812
Unique Selling Proposition (USP) — Building Pharmaceuticals Brands ALA 1,809
Wnt/β-catenin Signaling [7.10] LHB 1,777
The role of biomarkers in the diagnosis of sepsis and patient management LHB 1,766
Neonatal Pathophysiology LHB 1,718
Nanotechnology and MRI imaging TB 1,672
Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions JDP

ALA

1,659
Ultrasound-based Screening for Ovarian Cancer DN 1,655
Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert, Author, Writer, Editor & Content Consultant for e-SERIES A: Cardiovascular Diseases JDP 1,653
Scientific and Medical Affairs Chronological CV ALA 1,619
Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS) ALA 1,609
Stenting for Proximal LAD Lesions ALA 1,603
Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure? JDP

ALA

1,602
Nitric Oxide, Platelets, Endothelium and Hemostasis (Coagulation Part II) LHB 1,597
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB LHB 1,588
Diet and Diabetes LHB 1,572
Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination? ALA 1,546
Dealing with the Use of the High Sensitivity Troponin (hs cTn) Assays LHB 1,540
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers ALA 1,534
Altitude Adaptation LHB 1,527
Baby’s microbiome changing due to caesarean birth and formula feeding SS 1,498
Interview with the co-discoverer of the structure of DNA: Watson on The Double Helix and his changing view of Rosalind Franklin ALA 1,488
Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes ALA 1,476
IDO for Commitment of a Life Time: The Origins and Mechanisms of IDO, indolamine 2, 3-dioxygenase DS 1,469
CRISPR/Cas9: Contributions on Endoribonuclease Structure and Function, Role in Immunity and Applications in Genome Engineering LHB 1,468
Cancer Signaling Pathways and Tumor Progression: Images of Biological Processes in the Voice of a Pathologist Cancer Expert LHB 1,452
Signaling transduction tutorial LHB 1,443
Diagnostic Evaluation of SIRS by Immature Granulocytes LHB 1,440
UPDATED: PLATO Trial on ACS: BRILINTA (ticagrelor) better than Plavix® (clopidogrel bisulfate): Lowering chances of having another heart attack ALA 1,426
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease ALA 1,424
Nanotechnology and Heart Disease TB 1,419
Aviva Lev-Ari, PhD, RN, Director and Founder ALA 1,416
Cardiotoxicity and Cardiomyopathy Related to Drugs Adverse Effects LHB 1,415
Nitric Oxide and it’s impact on Cardiothoracic Surgery TB 1,405
A New Standard in Health Care – Farrer Park Hospital, Singapore’s First Fully Integrated Healthcare/Hospitality Complex GST 1,402
Mitochondrial Damage and Repair under Oxidative Stress LHB 1,398
Ovarian Cancer and fluorescence-guided surgery: A report TB 1,395
Sex determination vs. Sex differentiation SS 1,393
LPBI Group ALA 1,372
Closing the Mammography gap DN 1,368
Cytoskeleton and Cell Membrane Physiology LHB 1,367
Crucial role of Nitric Oxide in Cancer RS 1,364
Medical 3D Printing ALA 1,332
Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty LHB 1,325
The Final Considerations of the Role of Platelets and Platelet Endothelial Reactions in Atherosclerosis and Novel Treatments LHB 1,310
Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism

LHB

JDP

ALA

1,301
Mitochondrial Dynamics and Cardiovascular Diseases RS 1,284
Nitric Oxide and Immune Responses: Part 2 AV 1,282
Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors SJW 1,269
Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells using a bacterial CRISPR/Cas ALA 1,261
Autophagy LHB 1,255
Mitochondrial fission and fusion: potential therapeutic targets? RS 1,246
Summary of Lipid Metabolism LHB 1,239
Nitric Oxide has a Ubiquitous Role in the Regulation of Glycolysis – with a Concomitant Influence on Mitochondrial Function LHB 1,233
Future of Calcitonin…? Dr. Karra 1,211
Transcatheter Aortic Valve Implantation (TAVI): FDA approves expanded indication for two transcatheter heart valves for patients at intermediate risk for death or complications associated with open-heart surgery ALA 1,197
Gamma Linolenic Acid (GLA) as a Therapeutic tool in the Management of Glioblastoma

RN

MB

1,193
Nanotechnology and HIV/AIDS Treatment TB 1,181
Patiromer – New drug for Hyperkalemia ALA 1,179
‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly ALA 1,177
A Patient’s Perspective: On Open Heart Surgery from Diagnosis and Intervention to Recovery Guest Author: Ferez S. Nallaseth, Ph.D. 1,173
Assessing Cardiovascular Disease with Biomarkers LHB 1,167
Development Of Super-Resolved Fluorescence Microscopy LHB 1,166
Ubiquitin-Proteosome pathway, Autophagy, the Mitochondrion, Proteolysis and Cell Apoptosis: Part III LHB 1,162
Atrial Fibrillation contributing factor to Death, Autopsy suggests CEO Dave Goldberg had heart arrhythmia before death ALA 1,159
Linus Pauling: On Lipoprotein(a) Patents and On Vitamin C ALA 1,156
Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation ALA 1,154
The History of Hematology and Related Sciences LHB 1,151
Heroes in Medical Research: Barnett Rosenberg and the Discovery of Cisplatin SJW 1,146
Overview of New Strategy for Treatment of T2DM: SGLT2 Inhibiting Oral Antidiabetic Agents AV 1,143
Imatinib (Gleevec) May Help Treat Aggressive Lymphoma: Chronic Lymphocytic Leukemia (CLL) ALA 1,140
Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing SJW 1,137
New England Compounding Center: A Family Business AK 1,120
EpCAM [7.4] LHB 1,113
Amyloidosis with Cardiomyopathy LHB 1,110
Can Mobile Health Apps Improve Oral-Chemotherapy Adherence? The Benefit of Gamification. SJW 1,095
Acoustic Neuroma, Neurinoma or Vestibular Schwannoma: Treatment Options ALA 1,089
Treatment of Refractory Hypertension via Percutaneous Renal Denervation ALA 1,088
Proteomics – The Pathway to Understanding and Decision-making in Medicine LHB 1,085
Low Bioavailability of Nitric Oxide due to Misbalance in Cell Free Hemoglobin in Sickle Cell Disease – A Computational Model AS 1,085
Pancreatic Cancer: Genetics, Genomics and Immunotherapy TB 1,083
A NEW ERA OF GENETIC MANIPULATION   DS 1,075
Targeting Mitochondrial-bound Hexokinase for Cancer Therapy ZR 1,074
Normal and Anomalous Coronary Arteries: Dual Source CT in Cardiothoracic Imaging JDP

ALA

1,062
Transdermal drug delivery (TDD) system and nanotechnology: Part II TB 1,057
Lung Cancer (NSCLC), drug administration and nanotechnology TB 1,046
Pharma World: The Pharmaceutical Industry in Southeast Asia – Pharma CPhI 20-22 March, 2013, Jakarta International Expo, Jakarta, Indonesia ALA 1,045
Nitric Oxide and Sepsis, Hemodynamic Collapse, and the Search for Therapeutic Options LHB 1,044
Targeted delivery of therapeutics to bone and connective tissues: current status and challenges- Part I AV 1,044
Press Coverage ALA 1,036
Carbohydrate Metabolism LHB 1,036
Open Abdominal Aortic Aneurysm (AAA) repair (OAR) vs. Endovascular AAA Repair (EVAR) in Chronic Kidney Disease Patients – Comparison of Surgery Outcomes LHB

ALA

1,032
In focus: Melanoma Genetics RS 1,018
Cholesteryl Ester Transfer Protein (CETP) Inhibitor: Potential of Anacetrapib to treat Atherosclerosis and CAD ALA 1,015
Medical Devices Start Ups in Israel: Venture Capital Sourced Locally – Rainbow Medical (GlenRock) & AccelMed (Arkin Holdings) ALA 1,007
The Development of siRNA-Based Therapies for Cancer ZR 1,003

Other related articles published in this Open Access Online Scientific Journal include the following:

FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018

https://pharmaceuticalintelligence.com/2017/04/28/five-years-of-e-scientific-publishing-pharmaceuticalintellicence-com-top-articles-by-author-and-by-e-views-1000-4272012-to-4272017/

Read Full Post »


Live Conference Coverage @Medcitynews Converge 2018 Philadelphia:Liquid Biopsy and Gene Testing vs Reimbursement Hurdles

9:25- 10:15 Liquid Biopsy and Gene Testing vs. Reimbursement Hurdles

Genetic testing, whether broad-scale or single gene-testing, is being ordered by an increasing number of oncologists, but in many cases, patients are left to pay for these expensive tests themselves. How can this dynamic be shifted? What can be learned from the success stories?

Moderator: Shoshannah Roth, Assistant Director of Health Technology Assessment and Information Services , ECRI Institute @Ecri_Institute
Speakers:
Rob Dumanois, Manager – reimbursement strategy, Thermo Fisher Scientific
Eugean Jiwanmall, Senior Research Analyst for Medical Policy & Technology Evaluation , Independence Blue Cross @IBX
Michael Nall, President and Chief Executive Officer, Biocept

 

Michael: Wide range of liquid biopsy services out there.  There are screening companies however they are young and need lots of data to develop pan diagnostic test.  Most of liquid biopsy is more for predictive analysis… especially therapeutic monitoring.  Sometimes solid biopsies are impossible , limited, or not always reliable due to metastasis or tough to biopsy tissues like lung.

Eugean:  Circulating tumor cells and ctDNA is the only FDA approved liquid biopsies.  However you choose then to evaluate the liquid biopsy, PCR NGS, FISH etc, helps determines what the reimbursement options are available.

Rob:  Adoption of reimbursement for liquid biopsy is moving faster in Europe than the US.  It is possible in US that there may be changes to the payment in one to two years though.

Michael:  China is adopting liquid biopsy rapidly.  Patients are demanding this in China.

Reimbursement

Eugean:  For IBX to make better decisions we need more clinical trials to correlate with treatment outcome.  Most of the major cancer networks, like NCCN, ASCO, CAP, just have recommendations and not approved guidelines at this point.  From his perspective with lung cancer NCCN just makes a suggestion with EGFR mutations however only the companion diagnostic is approved by FDA.

Michael:  Fine needle biopsies are usually needed by the pathologist anyway before they go to liquid biopsy as need to know the underlying mutations in the original tumor, it just is how it is done in most cancer centers.

Eugean:  Whatever the established way of doing things, you have to outperform the clinical results of the old method for adoption of a newer method.

Reimbursement issues have driven a need for more research into clinical validity and utility of predictive and therapeutic markers with regard to liquid biopsies.  However although many academic centers try to partner with Biocept Biocept has a limit of funds and must concentrate only on a few trials.  The different payers use different evidence based methods to evaluate liquid biopsy markers.  ECRI also has a database for LB markers using an evidence based criteria.  IBX does sees consistency among payers as far as decision and policy.

NGS in liquid biopsy

Rob: There is a path to coverage, especially through the FDA.  If you have a FDA cleared NGS test, it will be covered.  These are long and difficult paths to reimbursement for NGS but it is feasible. Medicare line of IBX covers this testing, however on the commercial side they can’t cover this.  @IBX: for colon only kras or nras has clinical utility and only a handful of other cancer related genes for other cancers.  For a companion diagnostic built into that Dx do the other markers in the panel cost too much?

Please follow on Twitter using the following #hash tags and @pharma_BI

#MCConverge

#cancertreatment

#healthIT

#innovation

#precisionmedicine

#healthcaremodels

#personalizedmedicine

#healthcaredata

And at the following handles:

@pharma_BI

@medcitynews

Read Full Post »


5:00 – 5:45 PM Early Diagnosis Through Predictive Biomarkers, NonInvasive Testing

Reporter: Stephen J. Williams, Ph.D.

 

Diagnosing cancer early is often the difference between survival and death. Hear from experts regarding the new and emerging technologies that form the next generation of cancer diagnostics.

Moderator: Heather Rose, Director of Licensing, Thomas Jefferson University
Speakers:
Bonnie Anderson, Chairman and CEO, Veracyte @BonnieAndDx
Kevin Hrusovsky, Founder and Chairman, Powering Precision Health @KevinHrusovsky

Bonnie Anderson and Veracyte produces genomic tests for thyroid and other cancer diagnosis.  Kevin Hrusovksy and Precision Health uses peer reviewed evidence based medicine to affect precision medicine decision.

Bonnie: aim to get a truth of diagnosis.  Getting tumor tissue is paramount as well as properly preserved tissue.  They use deep RNA sequencing  and machine learning  in their clinically approved tests.

Kevin: Serial biospace entrepreneur.  Two diseases, cancer and neurologic, have been diseases which have been hardest to get reproducible and validated biomarkers of early disease.  He concentrates on protein biomarkers.

Heather:  FDA has recently approved drugs for early disease intervention.  However the use of biomarkers can go beyond patient stratification in clinical trials.

Kevin: 15 approved drugs for MS but the markers are scans looking for brain atrophy which is too late of an endpoint.  So we need biomarkers of early disease progression.  We can use those early biomarkers of disease progression so pharma can target those early biomarkers and or use those early biomarkers of disease progression  for endpoint

Bonnie: exciting time in the early diagnostics field. She prefers transcriptomics to DNA based methods such as WES or WGS (whole exome or whole genome sequencing).  It was critical to show data on the cost savings imparted by their transcriptomic based thryoid cancer diagnostic test for payers to consider this test eligible for reimbursement.

Kevin: There has been 20 million  CAT scans for  cancer but it is estimated 90% of these scans led to misdiagnosis. Biomarker  development  has revolutionized diagnostics in this disease area.  They have developed a breakthrough panel of ten protein biomarkers in serum which he estimates may replace 5 million mammograms.

All panelists agreed on the importance of regulatory compliance and the focus of new research should be on early detection.  In addition they believe that Dr. Gotlieb’s appointment to the FDA is a positive for the biomarker development field, as Dr. Gotlieb understands the potential and importance of early detection and prevention of disease.  Kevin also felt Dr. Gotlieb understands the importance of incorporating biomarkers as endpoints in clinical trials.  Over 750 phase 1,2, and 3 clinical trials use biomarker endpoints but the pharma companies still need to prove the biomarkers clinical relevance to the FDA.They also agreed it would be helpful to involve advocacy groups in putting more pressure on the healthcare providers and policy makers on this importance of diagnostics as a preventative measure.

In addition, the discovery and use of biomarkers as disease endpoints has led to a resurgence of Alzheimer’s disease drug development by companies which have previously given up on these type of neurodegenerative diseases.

Kevin feels proteomics offers great advantages over DNA-based diagnostics, especially in cancer such as ovarian cancer, where a high degree of specificity for a diagnostic test is required to ascertain if a woman should undergo prophylactic oophorectomy.  He suggests that a new blood-based protein biomarker panel is being developed for early detection of some forms of ovarian cancer.

Please follow on Twitter using the following #hash tags and @pharma_BI

#MCConverge

#cancertreatment

#healthIT

#innovation

#precisionmedicine

#healthcaremodels

#personalizedmedicine

#healthcaredata

And at the following handles:

@pharma_BI

@medcitynews

 

Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center

https://pharmaceuticalintelligence.com/press-coverage/

Read Full Post »


Survival Calls during Careers in the Digital Age

Curator: Aviva Lev-Ari, PhD, RN

 

As I shared with my friend, Aviva Brecher, MIT’68, an article that featured my career in May 2018 in the Alumni Spotlight of the Hebrew University,

My friend wrote the following:

From: Aviva Brecher
Date: Tuesday, May 8, 2018 at 9:40 AM
To: Aviva Lev-Ari
Subject: Re: Article about Aviva Lev-Ari ­in Spotlight of American Friends of the Hebrew University

Aviva:

You have an impressive education and career track with major reorientations. I too have reoriented and “reinvented” my career within the Applied Physics realm: from solid state physics and magnetism, to Lunar and Planetary Science and meteoritics in the Apollo age, to Earth Sciences and to applied topics like nuclear waste isolation and their advanced transportation technologies and environmental impacts.

 

I was very intrigued to further elucidate what actually are the Survival Calls during Careers in the Digital Age. That exploration was inspired by an additional new direction added to MIT Tech Review called: Clocking In, A daily look at the workplace of the future. 

In their 2/21/2018 article The fastest transition humankind has experienced” 

The reader is welcome to their annual list of the 10 technology advances they think will shape the way we work and live now and for years to come.

  • Genetic Fortune-Telling

We spotted Genomics technology and published a book about it

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

 

In Clocking In article on 3/9/2018 Robert Rubin is interviewed on How to prepare for the future of workHe runs the Hamilton Project, a DC-based think tank.

Rubin: McKinsey Global Institute put out a report recently in which they projected roughly one-third of American workers might have to change jobs or vacate the jobs they have by 2030. They also said that they thought that there would be opportunity for all kinds of increased employment in existing areas—like education, management, and technology—that will need more people. But, you need a lot of public policy to support that transition.

 

Labor Productivity and Automation

Autor, David, and Anna Salomons. 2018. “Is automation labor-displacing? Productivity growth, employment, and the labor share.” BPEA Conference Draft, Spring.

https://www.brookings.edu/bpea-articles/is-automation-labor-displacing-productivity-growth-employment-and-the-labor-share/

 

Technology Pipeline and Gender

  • The US tech talent pipeline shows promising signs for a more gender diverse future. (TR)
  • Women do hold the majority of STEM jobs—in Iran. (Quartz)

 

Clocking In, in their article on 6/7/2018, How we measure the gig economy matters

The Aspen Institute has put together its own data repository on gig work, and found that roughly 30 percent of the US workforce depends on the gig economy in some form.

The Bureau of Labor Statistics released its long-awaited 2017 Contingent Worker Supplement this morning—a huge event for us data nerds!—giving us a “current” (the data is from May 2017) view of gig work in the US. But there are a few problems with the findings.

Why it matters: Had the BLS report found a large jump in nontraditional workers, it might have caught the eye of Congress and motivated lawmakers to pass legislation that to protect and support gig economy workers (emphasis on the “might,” but still). Instead the report could be used to argue the gig economy isn’t as big or important as it’s cracked up to be.

 

We foresee the future to have major opportunities in the Expert Consultancy private sector. By 2030 freelance consultants with very deep expertise will hold the knowledge that corporations need for in-house technology development. It will bring a golden age to a new breed of PhD level experts foot loose providing services to multiple employers. It is a version of the gig economy at the highest pay rate per hour.

 

With generous funding and top-tier jobs, China seeks to lure science talent from abroad

http://www.sciencemag.org/news/2018/06/generous-funding-and-top-tier-jobs-china-seeks-lure-science-talent-abroad

 

We foresee the future of Markets experiencing brain drain and other Markets experiencing brain influx. The knowledge worker will trade his skills on a global scale and will be geographically, foot loose.

The knowledge worker will be subjected to unique survival calls, will have multiple careers in a life time and will re-invent their avocation and the skill offering per an unprecedented fast pace of structural changes in the economy and fluctuation in demand for ever newly minted talent.

  • While “Agility” was the pace of the 90s,
  • the 2020s will be the decade of “re-orientation driven by technological innovation of Artificial intelligence embedded in tools performing tasks by automation and a new era for robotics empowered by rule-based decision support software, actually, autonomous decision making, remotely supervised. 

 

In that light, I submitted a story pitch to Clocking In:

From: MIT Technology Review <pitches-and-tips@technologyreview.com

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Date: 
Wednesday, June 13, 2018 at 3:37 PM

Subject: Re: It is a Case Study for Clocking In about Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL

We have received your news tip or story pitch. Thank you!

Our editors review every item submitted, and we’ll be in touch if we’d like to pursue your submission or learn more. 

Thanks for your interest in MIT Technology Review.

 

Supporting material to the story pitch include the following:

 

  • Thriving at the Survival Calls during Careers in the Digital Age – An AGE like Other, also known as, DIGITAL

https://pharmaceuticalintelligence.com/2018/06/11/thriving-at-the-survival-calls-during-careers-in-the-digital-age-an-age-like-no-other-also-known-as-digital/

 

  • Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

 

  • Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

 

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

 

  • Professional Self Re-Invention: From Academia to Industry – Opportunities for PhDs in the Business Sector of the Economy

https://pharmaceuticalintelligence.com/2018/05/22/professional-self-re-invention-from-academia-to-industry-opportunities-for-phds-in-the-business-sector-of-the-economy/

 

  • Key Opinion Leader (KOL) in Pharmaceutical Business Intelligence – Aviva Lev-Ari, PhD, RN, as evidenced by

https://pharmaceuticalintelligence.com/2016/07/21/key-opinion-leader-kol-aviva-lev-ari-phd-rn-as-evidenced-by/

 

  • Data Science is the Greatest Science! It is the Greatest Science for Women, as well

https://pharmaceuticalintelligence.com/2018/03/12/data-science-is-the-greatest-science-it-is-the-greatest-science-for-women-as-well/

 

Read Full Post »


Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL

Author and Curator: Aviva Lev-Ari, PhD, RN

 

The source for the inspiration to write this curation is described in

Survival Calls during Careers in the Digital Age

https://pharmaceuticalintelligence.com/2018/06/13/survival-calls-during-careers-in-the-digital-age/

 

In this curation, I present the following concepts in three parts:

  1. Part 1: Authenticity of Careers in the Digital Age: In Focus, the BioTechnology Sector
  2. Part 2: Top 10 books to help you survive the Digital Age

  3. Part 3: A case study on Thriving at the Survival Calls during Careers in the Digital Age: Aviva Lev-Ari, UCB, PhD’83; HUJI, MA’76 

 

Part 1: Authenticity of Careers in the Digital Age: 

In Focus, the BioTechnology Sector

 

Lisa LaMotta, Senior Editor, BioPharma Dive wrote in Conference edition | June 11, 2018

Unlike that little cancer conference in Chicago last week, the BIO International convention is not about data, but about the people who make up the biopharma industry.

The meeting brings together scientists, board members, business development heads and salespeople, from the smallest virtual biotechs to the largest of pharmas. It allows executives at fledgling biotechs to sit at the same tables as major decision-makers in the industry — even if it does look a little bit like speed dating.

But it’s not just a partnering meeting.

This year’s BIO also sought to shine a light on pressing issues facing the industry. Among those tackled included elevating the discussion on gender diversity and how to bring more women to the board level; raising awareness around suicide and the need for more mental health treatments; giving a voice to patient advocacy groups; and highlighting the need for access to treatments in developing nations.

Four days of meetings and panel discussions are unlikely to move the needle for many of these challenges, but debate can be the first step toward progress.

I attended the meetings on June 4,5,6, 2018 and covered in Real Time the sessions I attended. On the link below, Tweets, Re-Tweets and Likes mirrors the feelings and the opinions of the attendees as expressed in real time using the Twitter.com platform. This BioTechnology events manifested the AUTHENTICITY of Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL.

The entire event is covered on twitter.com by the following hash tag and two handles:

 

I covered the events on two tracks via two Twitter handles, each handle has its own followers:

The official LPBI Group Twitter.com account

The Aviva Lev-Ari, PhD, RN Twitter.com account

Track A:

  • Original Tweets by @Pharma_BI and by @AVIVA1950 for #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/06/11/original-tweets-by-pharma_bi-and-by-aviva1950-from-bio2018-iambiotech-bioconvention-bio-2018-boston-june-4-7-2018-bcec/

 

  • Reactions to Original Tweets by @Pharma_BI and by @AVIVA1950 from #BIO2018

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/06/12/reactions-to-original-tweets-by-pharma_bi-and-by-aviva1950-from-bio2018/

Track B:

  • Re-Tweets and Likes by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/06/11/re-tweets-and-likes-by-pharma_bi-aviva1950-from-bio2018-iambiotech-bioconvention-bio-2018-boston-june-4-7-2018-bcec/

Part 2: Top 10 books to help you survive the digital age

From Philip K Dick’s obtuse robots to Mark O’Connell’s guide to transhumanism, novelist Julian Gough picks essential reading for a helter skelter world

Here are 10 of the books that did help me [novelist Julian Gough]: they might also help you understand, and survive, our complicated, stressful, digital age.

  1. Marshall McLuhan Unbound by Marshall McLuhan (2005)
    The visionary Canadian media analyst predicted the internet, and coined the phrase the Global Village, in the early 1960s. His dense, complex, intriguing books explore how changes in technology change us. This book presents his most important essays as 20 slim pamphlets in a handsome, profoundly physical, defiantly non-digital slipcase.
  2. Ubik by Philip K Dick (1969)
    Pure pulp SF pleasure; a deep book disguised as a dumb one. Dick shows us, not a dystopia, but a believably shabby, amusingly human future. The everyman hero, Joe Chip, wakes up and argues with his robot toaster, which refuses to toast until he sticks a coin in the slot. Joe can’t do this, because he’s broke. He then has a stand-up row with his robot front door, which won’t open, because he owes it money too … Technology changes: being human, and broke, doesn’t. Warning: Dick wrote Ubik at speed, on speed. But embedded in the pulpy prose are diamonds of imagery that will stay with you for ever.
  3. The Singularity Is Near by Ray Kurzweil (2005)
    This book is what Silicon Valley has instead of a bible. It’s a visionary work that predicts a technological transformation of the world in our lifetime. Kurzweil argues that computer intelligence will soon outperform human thought. We will then encode our minds, upload them, and become one with our technology, achieving the Singularity. At which point, the curve of technological progress starts to go straight up. Ultimately – omnipotent, no longer mortal, no longer flesh – we transform all the matter in the universe into consciousness; into us.
  4. To Be a Machine by Mark O’Connell (2017)
    This response to Kurzweil won this year’s Wellcome prize. It’s a short, punchy tour of transhumanism: the attempt to meld our minds with machines, to transcend biology and escape death. He meets some of the main players, and many on the fringes, and listens to them, quizzically. It is a deliberately, defiantly human book, operating in that very modern zone between sarcasm and irony, where humans thrive and computers crash.
  5. A Visit from the Goon Squad by Jennifer Egan (2011)
    This intricately structured, incredibly clever novel moves from the 60s right through to a future maybe 15 years from now. It steps so lightly into that future you hardly notice the transition. It has sex and drugs and rock’n’roll, solar farms, social media scams and a stunningly moving chapter written as a PowerPoint presentation. It’s a masterpiece. Life will be like this.
  6. What Technology Wants by Kevin Kelly (2010)
    Kelly argues that we scruffy biological humans are no longer driving technological progress. Instead, the technium, “the greater, global, massively interconnected system of technology vibrating around us”, is now driving its own progress, faster and faster, and we are just caught up in its slipstream. As we accelerate down the technological waterslide, there is no stopping now … Kelly’s vision of the future is scary, but it’s fun, and there is still a place for us in it.
  7. The Meme Machine by Susan Blackmore (1999)
    Blackmore expands powerfully and convincingly on Richard Dawkins’s original concept of the meme. She makes a forceful case that technology, religion, fashion, art and even our personalities are made of memes – ideas that replicate, mutate and thus evolve over time. We are their replicators (if you buy my novel, you’ve replicated its memes); but memes drive our behaviour just as we drive theirs. It’s a fascinating book that will flip your world upside down.
  8. Neuromancer by William Gibson (1984)
    In the early 1980s, Gibson watched kids leaning into the screens as they played arcade games. They wanted to be inside the machines, he realised, and they preferred the games to reality. In this novel, Gibson invented the term cyberspace; sparked the cyberpunk movement (to his chagrin); and vividly imagined the jittery, multi-screened, anxious, technological reality that his book would help call into being.
  9. You Are Not a Gadget: A Manifesto by Jaron Lanier (2010)
    Lanier, an intense, brilliant, dreadlocked artist, musician and computer scientist, helped to develop virtual reality. His influential essay Digital Maoism described early the downsides of online collective action. And he is deeply aware that design choices made by (mainly white, young, male) software engineers can shape human behaviour globally. He argues, urgently, that we need to question those choices, now, because once they are locked in, all of humanity must move along those tracks, and we may not like where they take us. Events since 2010 have proved him right. His manifesto is a passionate argument in favour of the individual voice, the individual gesture.
  10. All About Love: New Visions by bell hooks (2000)
    Not, perhaps, an immediately obvious influence on a near-future techno-thriller in which military drones chase a woman and her son through Las Vegas. But hooks’s magnificent exploration and celebration of love, first published 18 years ago, will be far more useful to us, in our alienated digital future, than the 10,000 books of technobabble published this year. All About Love is an intensely practical roadmap, from where we are now to where we could be. When Naomi and Colt find themselves on the run through a militarised American wilderness of spirit, when GPS fails them, bell hooks is their secret guide.

SOURCE

https://www.theguardian.com/books/2018/may/30/top-10-books-to-help-you-survive-the-digital-age?utm_source=esp&utm_medium=Email&utm_campaign=Bookmarks+-+Collections+2017&utm_term=277690&subid=25658468&CMP=bookmarks_collection

Part 3: A case study on Thriving at the Survival Calls during Careers in the Digital Age:  Aviva Lev-Ari, UCB, PhD’83; HUJI, MA’76

 

On June 10, 2018

 

Following, is a case study about an alumna of HUJI and UC, Berkeley as an inspirational role model. An alumna’s profile in context of dynamic careers in the digital age. It has great timeliness and relevance to graduate students, PhD level at UC Berkeley and beyond, to all other top tier universities in the US and Europe. As presented in the following curations:

Professional Self Re-Invention: From Academia to Industry – Opportunities for PhDs in the Business Sector of the Economy

https://pharmaceuticalintelligence.com/2018/05/22/professional-self-re-invention-from-academia-to-industry-opportunities-for-phds-in-the-business-sector-of-the-economy/

 

Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI, MA’76 

https://pharmaceuticalintelligence.com/2018/05/28/pioneering-implementations-of-analytics-to-business-decision-making-contributions-to-domain-knowledge-conceptualization-research-design-methodology-development-data-modeling-and-statistical-data-a/

 

This alumna is Editor-in-Chief of a Journal that has other 173 articles on Scientist: Career Considerations 

https://pharmaceuticalintelligence.com/category/scientist-career-considerations/

 

In a 5/22/2018 article, Ways to Pursue Science Careers in Business After a PhD by Ankita Gurao,

https://bitesizebio.com/38498/ways-to-pursue-the-business-of-science-after-a-ph-d/?utm_source=facebook&utm_medium=social&utm_campaign=SocialWarfare

Unemployment figures of PhDs by field of science are included, Ankita Gurao identifies the following four alternative careers for PhDs in the non-academic world:

  1. Science Writer/Journalist/Communicator
  2. Science Management
  3. Science Administration
  4. Science Entrepreneurship

My career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

has the following phases:

  • Phase 1: Research, 1973 – 1983
  • Phase 2: Corporate Applied Research in the US, 1985 – 2005
  • Phase 3: Career Reinvention in Health Care, 2005 – 2012
  • Phase 4: Electronic Scientific Publishing, 4/2012 to present

These four phases are easily mapped to the four alternative careers for PhDs in the non-academic world. One can draw parallel lines between the four career opportunities A,B,C,D, above, and each one of the four phases in my own career.

Namely, I have identified A,B,C,D as early as 1985, and pursued each of them in several institutional settings, as follows:

A. Science Writer/Journalist/Communicator – see link above for Phase 4: Electronic Scientific Publishing, 4/2012 to present 

B. Science Management – see link above for Phase 2: Corporate Applied Research in the US, 1985 – 2005 and Phase 3: Career Reinvention in Health Care, 2005 – 2012 

C. Science Administration – see link above for Phase 2: Corporate Applied Research in the US, 1985 – 2005and Phase 4: Electronic Scientific Publishing, 4/2012 to present 

D. Science Entrepreneurship – see link above for Phase 4: Electronic Scientific Publishing, 4/2012 to present  

Impressions of My Days at Berkeley in Recollections: Part 1 and 2, below.

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 –About my doctoral advisor, Allan Pred, other professors and other peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

The topic of Careers in the Digital Age is closely related to my profile, see chiefly: Four-phase Career, Reflections, Recollections Parts 1 & 2 and information from other biographical sources, below.

Other sources for my biography

 

Read Full Post »

Older Posts »